CHF Solutions to Sponsor CT Theatre Session, “Personalized Medicine: Improving Clinical Outcomes with Novel Fluid Managemen...
April 23 2019 - 8:30AM
CHF Solutions (Nasdaq: CHFS), today announced it will be sponsoring
a CT Theatre Session at the American Association for Thoracic
Surgery Annual Meeting on Monday, May 6, 2019, 1:00-1:30 pm at the
Metro Toronto Convention Center.
The panel titled, “Personalized Medicine: Improving Clinical
Outcomes with Novel Fluid Management Strategies,” will include
discussion on the use of the Aquadex FlexFlow® System to help
manage risks associated with fluid overload in adult cardiac
surgery patients. The discussion will be moderated by Daniel
Beckles, M.D., Ph.D. (United Health Services Hospitals-Binghamton)
and panel members will include Margarita Camacho, M.D. (Newark Beth
Israel), Mehdi Oloomi, M.D. (Mount Sinai Health System), and Mark
Small, M.S., PA-C (Medstar Franklin Square). In addition, the
company will be exhibiting at the meeting in Booth #611, Hall A-C,
during the conference, which is held from May 4-7.
“The use of ultrafiltration in post-cardiovascular surgery
provides medical providers with an important solution to treat
fluid overload,” said John Erb, chairman and CEO of CHF Solutions.
“We are pleased to have Dr. Beckles moderate such a distinguished
panel of industry experts for this CT Theatre Session and provide
practitioners on clinical methodologies to optimize treatment
outcomes in the post cardiovascular surgery setting.”
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company
focused on commercializing the Aquadex FlexFlow system for
aquapheresis therapy. The Aquadex FlexFlow system is indicated for
temporary (up to eight hours) ultrafiltration treatment of patients
with fluid overload who have failed diuretic therapy and extended
(longer than 8 hours) ultrafiltration treatment of patients with
fluid overload who have failed diuretic therapy and require
hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom
having received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance
through science, collaboration, and innovative medical technology.
CHF Solutions is a Delaware corporation headquartered in
Minneapolis, Minnesota with wholly owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, the company’s plans for the American Association for
Thoracic Surgery Annual Meeting. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our commercial strategy, the possibility that we may be unable to
raise sufficient funds necessary for our anticipated operations,
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. CHF Solutions does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
CONTACTS:
INVESTORS:Claudia Napal DraytonChief Financial
Officer CHF Solutions, Inc.952-345-4205ir@chf-solutions.com
-or-Bret Shapiro Managing Partner CORE
IR516-222-2560brets@coreir.com www.coreir.com
MEDIAJules Abraham JQA Partners, Inc.
917-885-7378jabraham@jqapartners.com
Source: CHF Solutions, Inc.
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024